Whitby,1 in May 1938, reported experiments showing that 2-(p-aminobenzenesulfonamido) pyridine (M & B 693, T 693, Dagenan; referred to in this report as sulfapyridine2) is chemotherapeutically active in experimental infections in mice against pneumococci of types I, II, III, V, VII, VIII and particularly against types I, VII and VIII, protecting against 10,000 lethal doses of type I. In Whitby's experience, it was the one compound observed to be effective against the pneumococcus in the assessment of more than sixty-four compounds related to sulfanilamide. He reported also that this drug is as effective as sulfanilamide against hemolytic streptococci and meningococci. This compound is a white, crystalline, almost tasteless solid, soluble in water at ordinary temperatures to the extent of approximately one part in 1,000. It has the constitutional formula From the formula, it will be seen that the compound differs from sulfanilamide in that one hydrogen
BARNETT HL, HARTMANN AF, PERLEY AM, RUHOFF MB. THE TREATMENT OF PNEUMOCOCCIC INFECTIONS IN INFANTS AND CHILDREN WITH SULFAPYRIDINE. JAMA. 1939;112(6):518–527. doi:10.1001/jama.1939.02800060034007
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: